Campaign 2010

Oct 24, 2006

The Truth About Nancy Johnson’s Record on Medicare

DCCC Press

Oct 24, 2006

The Truth About Nancy Johnson’s Record on Medicare

Connecticut Families Deserve Truth, not More Campaign Trail Rhetoric, Especially as Drug Prices Continue to Soar

$739,000 Amount of money Nancy Johnson, co-author of the Medicare Part D bill, has taken from Pharmaceutical companies. []

#2 Nancy Johnson’s ranking of all House members in drug company donations since 1990. []

537,386 Medicare beneficiaries in Connecticut. []

86,855 Connecticut seniors who could fall into the doughnut hole. [House Committee on Ways and Means Report, 9/21/06]

163 Days since Medicare Part D enrollment deadline during which time, Johnson has done nothing to fix the donut hole or penalties seniors face

(Washington, D.C.) – Recent attempts by Congresswoman Nancy Johnson and her supporters to tout her credentials on Medicare do not match her record on the issue. Connecticut families are looking for a change from Johnson, who is one of the top recipients of prescription drug money in Congress and one of the key architects of the special interest Medicare prescription drug bill. Johnson has also refused to allow Medicare to negotiate for the best prices for Connecticut families and there are over 500,000 Medicare beneficiaries in Connecticut and nearly 90,000 who could fall into the gap in coverage known as the doughnut hole. The Medicare bill has been evidence that the big drug companies have a vested interest in the Republican Congress. The bill, as so many seniors now know, is confusing, expensive and clearly benefits the pharmaceutical companies and HMOs. Nancy Johnson and her GOP colleagues have taken millions from big drug companies and HMOs and in return, those big special interests have benefited while seniors pay more.

“Voters in Connecticut deserve to know the truth about Nancy Johnson’s record on health care. There’s a reason why she’s one of the top recipients of prescription drug money in Congress and why the drug companies get exactly what they want from her in Congress – more giveaways,” said Bill Burton, communications director of the Democratic Congressional Campaign Committee. “Nancy Johnson was one of the key architects of the Medicare bill that is confusing, expensive and clearly a benefit to the drug companies and HMOs. It’s time for a new direction in Congress because Connecticut families struggling with expensive health care bills deserve affordable prescription drugs and Nancy Johnson opposes negotiating for the best prices possible.”

Nancy Johnson Opposes Medicare Price Negotiation. On her 2006 AARP candidate questionnaire, Johnson checked the box indicating that she opposed, “Medicare negotiating to lower drug prices.” [2006 AARP Questionnaire,]

Johnson Has Taken Over $739,000 From Big Drug Companies; Second Most in the House. In her campaigns for Congress, Nancy Johnson has raised $739,530 from the pharmaceutical industry, making her the second largest recipient of Rx drug contributions of any current member of the House. []

  • Johnson was Top Recipient Leading Up to Medicare Bill. In the 2002 cycle, the two years before the Medicare prescription drug bill was written, Johnson was the top congressional recipient of money from the pharmaceutical industry, raking in over $211,000. []

Johnson Described Herself as a “Key Architect” of the Bill. In 2003, after the Medicare prescription drug bill was passed, Johnson issued a press release that stated that she was a “key architect” of the bill. [Johnson release, 11/22/03; WTNH, 2/23/06]

Connecticut Seniors Have Nancy Johnson to Thank for GOP Medicare Prescription Drug Bill which Increased Premiums and Created a Growing Gap in Coverage. In 2003, the Nancy Johnson and the Rubber Stamp Republican Congress voted for a GOP bill that made sweeping changes to Medicare that will give billions of dollars to businesses and the health care industry, while forcing seniors to accept annual increases in premiums and deductibles, and a growing gap in coverage for the prescription drugs they buy. Initial deductibles are projected to rise dramatically. By the eighth year of the program, the deductible and the coverage gap are both projected to grow by 78 percent. Insurance premiums, are projected to increase 65 percent by 2013. Meanwhile, the bill will give $139 billion in taxpayer dollars to businesses and the health care industry. [HR 1, Vote #669, 11/21/2003; Associated Press, 11/26/03; Washington Post, 11/24/03]